A Phase 1 Open-label, Randomized, Parallel-group Study to Assess the Relative Bioavailability of Rocatinlimab (AMG 451) Vial and Prefilled Syringe in Healthy Subjects
Latest Information Update: 01 Oct 2024
At a glance
- Drugs Rocatinlimab (Primary)
- Indications Atopic dermatitis
- Focus Pharmacokinetics
- Sponsors Amgen
Most Recent Events
- 27 Sep 2024 Status changed from active, no longer recruiting to completed.
- 23 May 2024 Status changed from recruiting to active, no longer recruiting.
- 10 Apr 2024 Planned End Date changed from 19 Aug 2024 to 29 Aug 2024.